WO2002096418A1 - Pirenzepine ophthalmic gel - Google Patents

Pirenzepine ophthalmic gel Download PDF

Info

Publication number
WO2002096418A1
WO2002096418A1 PCT/US2002/013823 US0213823W WO02096418A1 WO 2002096418 A1 WO2002096418 A1 WO 2002096418A1 US 0213823 W US0213823 W US 0213823W WO 02096418 A1 WO02096418 A1 WO 02096418A1
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
pirenzepine
myopia
sodium
gelling agent
Prior art date
Application number
PCT/US2002/013823
Other languages
French (fr)
Inventor
Harun Takruri
Original Assignee
Valley Forge Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MXPA03010655A priority Critical patent/MXPA03010655A/en
Priority to IL15890402A priority patent/IL158904A0/en
Priority to CA002447562A priority patent/CA2447562A1/en
Priority to BR0210013-4A priority patent/BR0210013A/en
Priority to HU0304071A priority patent/HUP0304071A2/en
Priority to KR10-2003-7015393A priority patent/KR20040018380A/en
Application filed by Valley Forge Pharmaceuticals filed Critical Valley Forge Pharmaceuticals
Priority to EP02734130A priority patent/EP1397132A4/en
Priority to JP2002592928A priority patent/JP2004531569A/en
Publication of WO2002096418A1 publication Critical patent/WO2002096418A1/en
Priority to US10/698,320 priority patent/US20040137069A1/en
Priority to NO20035224A priority patent/NO20035224D0/en
Priority to US11/400,635 priority patent/US20060188576A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention is in the field of aqueous ophthalmic pharmaceutical formulations.
  • a selected concentration of pirenzepine may prevent myopia without inducing unwanted side effects such as disabling mydriasis and cycloplegia.
  • Pirenzepine is a relatively selective Ml -muscarinic antagonist. It is being investigated for its topical ocular use to moderate and halt the progression of pediatric myopia. Administered as a solution in up to 2% strength, it was found comfortable and without systemic effects in adult volunteers (Shedden AH, Sciberras D, Hutzelmann J, and C van Nispen. 1998. Tolerability of pirenzepine ophthalmic solution in adult male volunteers. Invest. Ophthalmol. Vis. Sci. 39: S279.). However, work on a solution dosage form of pirenzepine indicated a physical appearance problem. Pirenzepine is stable in solution especially at pH 5, but its degradation product is insoluble in water.
  • aqueous ophthalmic formulation for treating myopia, comprising pirenzepine in combination with a pharmaceutically acceptable gel carrier.
  • a pharmaceutically acceptable gel carrier for treating myopia.
  • the ophthalmic aqueous gel formulation of the present invention for treating myopia comprises a pharmaceutically effective amount of pirenzepine in combination with a water soluble cellulose derivative.
  • the concentration of the pirenzepine in the present formulation may range from about 0.001 to 3% (w/v), preferably about 0.005 to 2% (w/v).
  • Pirenzepine and its dihydrochloride salt are known in the art.
  • Cellulose derivatives are used as gelling agents in the formulation of this invention. Most preferred is hydroxypropyl methylcellulose. Any cellulose derived gelling agent, however, that forms an aqueous gel at the desired viscosity, i.e., is soluble in water and forms a gel, can be used. Such derivatives are well known, as are their properties, and are described, e.g., in the U.S. Pharmacopeia (2000) (UNITED STATES PHARMACOPEIAL CONVENTION, INC., THE UNITED STATES PHARMACOPEIA/THE NATIONAL FORMULARY (2000)).
  • Such gelling agents include, but are not limited to, methyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, hydroxyethyl cellulose, and cellulose gum. Combinations of various derivatives may also be used.
  • Cellulose based gelling agents are advantageous over, for example, cross-linked acrylic polymers.
  • CarbopolTM a cross-linked acrylic polymer, has been used to form an aqueous gel containing pilocarpine hydrochloride for ophthalmic use.
  • Cellulose based gelling agents are less likely to cause adverse reactions.
  • the formulations of the invention are substantially viscous enough to form a viscous gel.
  • the viscosity preferably is in the range of 10,000 to 300,000 centipoise (cps), most preferably 15,000-200,000 cps, at about 20 °C and shear rate of Is "1 based on Brookfield RVDV analysis.
  • the amount of cellulose based gelling agent is preferably from about 0.5 wt. % to 5 wt. %, most preferably from about 1 wt. % to 5 wt.
  • Suitable cellulose based preparations for use in the invention are commonly commercially available.
  • sources of hydroxypropyl methylcellulose that are suitable for making a cellulose based ophthalmic gel according to the invention include Ashland Distribution Co., Asiaamerica International Inc., Biddle Sawyer Corp., Carbomer
  • the formulation may contain additional pharmaceutically inactive substances.
  • it may contain one or more solubilizing agents, such as polysorbate 20, polysorbate 40, polysorbate 60, or polysorbate 80.
  • the formulation may also contain a dispersant, such as lecithin or glycerin. Collagen can also be added.
  • Other additives include cyclodextrins, in particular alpha, beta, and gamma cyclodextrins.
  • vitamin E particularly in solubilized form, or other antioxidants, including butylate hydroxyanisole (BHA) and butylate hydroxytoluene (BHT), may be added.
  • inactives sodium chloride, cetrimide, thimerosal, benzalkonium chloride, boric acid, sodium carbonate, potassium chloride, propylene glycol, polyoxyethylene, polyoxypropylene, polyoxyl 40 stereate, polyvinyl alcohol, poloxamer 188, sodium citrate, sodium thiosulfate, sodium bisulfite, dextran 70, acetic acid, polyethylene glycol, povidone, dextrose, magnesium chloride, alginic acid, sodium acetate, sodium borate, edetate disodium, sodium hydroxide, and hydrochloric acid.
  • the optimal amount of inactive ingredient employed in the formulation can be conventionally determined based on the particular active pharmaceutical, and the intended use.
  • the formulation of the invention can be placed in any desired dispensing device suitable for an ophthalmic formulation.
  • the device can be an ophthalmic delivery system such as a sterile ophthalmic tube, for example, a conventional 3.5-5 g tube having an ophthalmic tip and containing the ophthalmic formulation of the invention, or a sterile, single or daily use container containing 0.1-0.5 g of the formulation.
  • the pharmaceutical formulations can be administered via various routes including ocular instillation, subconjuctival administration, and intravitreal administration.
  • a typical daily dose of pirenzepine may range 6 mg or less/whole body weight, preferably 4 mg or less/whole body weight, and can be administered in a single dose or in divided doses.
  • the amount of pirenzepine actually administered ought to be determined in light of various relevant factors including the myopia to be treated, the chosen route of administration and the severity of the patient's symptom; and, therefore, the above dose should not be intended to limit the scope of the invention in any way.
  • the stability data generated on the gel and solution dosage forms show the superiority of the gel over the solution in maintaining an acceptable physical appearance in the presence of the small amounts of the water-insoluble degradation product refen-ed to in the background of the invention.
  • Example 1 An aqueous ophthalmic gel of 2.0% pirenzepine for the treatment of myopia according to the present invention was prepared as follows:
  • Part 1 Purified water was heated to 80-90 °C. Hydroxypropyl methylcellulose (HPMC) was added and mixed until it was uniformly dispersed. The pH was adjusted to 5.0 ⁇ 1.0 with sodium hydroxide, but this was not a critical step and can be eliminated. After being placed in a pressure vessel, the mixture was sterilized at 121 °C for 30-45 minutes. In another embodiment, autoclaving is conducted under nitrogen when oxygen plays a role in viscosity loss upon autoclaving. The mixture was cooled to 25° to 30 °C and mixed for several hours to yield a homogenous viscous gel.
  • HPMC Hydroxypropyl methylcellulose
  • Part 2 The rest of the ingredients were mixed and dissolved in water until a clear solution was obtained. The pH was adjusted to 5.0 ⁇ 1.0 with sodium hydroxide. The solution was sterilized by membrane filtration (0.2 microns). The concentration of pirenzepine is calculated based on the free base. However, we added its dihydrochloride salt. By adjusting the pH to 5.0 + 1.0 with sodium hydroxide, the dihydrochloride salt is partially or completely converted to the monohydrochloride salt.
  • Part 2 The solution of Part 2 was aseptically added to the gel of Part 1. Sufficient sterile water was added to q.s. to the final weight of the batch. A final pH adjustment was made, if necessary. The batch was mixed for about 48 hours to achieve homogeneity. A gel resulted that was used to aseptically fill pre-sterilized ophthalmic containers.
  • the ophthalmic pirenzepine gel preparation made in Example 1 was administered as follows (the ophthalmic tip of the dispensing mechanism did not touch any surface to avoid contamination).
  • the lower lid of the eye to be administered was pulled down and a small amount of gel (approximately 0.25 inches) was applied to the inside of the eyelid.
  • the gel was applied to the afflicted eye twice per day.
  • a gel formulation in a target population of pediatric subjects was well tolerated.
  • Example 3 Procedure for Viscosity Measurement: A Brookfield Cone and Plate Viscometer (Model RVDV-III+) was used to measure viscosity at about 20°C and shear rate of Is "1 .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

It is a primary object of the present invention to provide an aqueous ophthalmic formulation, for treating myopia, comprising pirenzepine in combination with a pharmaceutically acceptable gel carrier.

Description

PIRENZEPINE OPHTHALMIC GEL
Background of the Invention Field of the Invention
The present invention is in the field of aqueous ophthalmic pharmaceutical formulations.
Background of the Invention Myopia, axial elongation of the eye, affects a large proportion of the population.
Commonly, the onset of myopia is during the grade school years and progresses until growth of the eye is completed. A pharmacologic therapy which prevents or retards the developmental abnoraiality of myopia would represent a major advance in the treatment of myopia. The potential use for a pharmacologic therapy has been stimulated by evidence that atropine prevents the development of myopia in humans (DA Goss. 1982. Attempts to reduce the rate of increase of myopia in young people—a critical literature review. Am. J. Optom. Physiol. Opt. 59: 828-841.), tree shrews (McKanna JA, and VA Casagrande. 1978. Reduced lens development in lid-suture myopia. Exp. Eye Res. 26: 715-723.), stump-tailed monkeys and chicks (McBrien NA, Moghaddam HO, Reeder AP, and S.
Moules. 1991a. Structural and biochemical changes in the sclera of experimentally myopic eyes. Biochem. Soc. Trans. 19: 861-865; McBrien NA, Moghaddam HO, and AP Reeder. 1991b. Atropine reduces axial elongation and myopia in visually impaired chick eyes. Invest. Ophthalmol. Vis. Sci. 32: 1203; Tigges M, Sugrue MF, Mallorga P, Stone RA, Laties AM, Fernandes A, and PM Iuvone. 1996. Effects of atropine, ATR, and pirenzepine, PIR, on ocular growth and muscarinic cholinergic receptors in young rhesus monkeys. Invest. Ophthalmol. Vis. Sci. 37: S326.). The clinical use of atropine as a therapy has been limited due to its ocular side effects including glare from pupillary dilation and blurred vision due to loss of accommodation. Mild cycloplegic agents like tropicamide have been effective in a number of studies but failed in other studies (Curtin
BJ and DB Karlin. 1971. Axial length measurements and fundus changes of the myopic eye. Am. J. Ophthalmol. 71: 42-53.). Stone and Laties found that subconjunctival injections of atropine, a nonselective muscarinic antagonist, and pirenzepine, a relatively selective Ml -antagonist marketed for systemic use in Europe for its anti-dyspepsia properties, attenuated axial eye growth in a chick model of myopia. M2 and M3 antagonists did not prevent axial elongation (Stone RA, Lin T, and AM Laties. 1991. Muscarinic antagonist effects on experimental chick myopia. Exp. Eye Res. 52: 755-758; U.S. Patent No. 5,112,522, Filed May 11, 1990.). Unlike atropine, a selected concentration of pirenzepine may prevent myopia without inducing unwanted side effects such as disabling mydriasis and cycloplegia.
Pirenzepine is a relatively selective Ml -muscarinic antagonist. It is being investigated for its topical ocular use to moderate and halt the progression of pediatric myopia. Administered as a solution in up to 2% strength, it was found comfortable and without systemic effects in adult volunteers (Shedden AH, Sciberras D, Hutzelmann J, and C van Nispen. 1998. Tolerability of pirenzepine ophthalmic solution in adult male volunteers. Invest. Ophthalmol. Vis. Sci. 39: S279.). However, work on a solution dosage form of pirenzepine indicated a physical appearance problem. Pirenzepine is stable in solution especially at pH 5, but its degradation product is insoluble in water. Thus, the accumulation of even a small amount of degradation product over the shelf-life of the solution results in an unacceptable product due to the unattractive appearance of the precipitate in the solution. There are no "standard" formulation solutions for such a problem. One approach is to use a refrigerated solution. Another approach is to use a lyophilized product for reconstitution prior to dispensing to the patient. However, neither of these approaches is optimal. Lyophilization adds considerably to the cost of the product and requires cumbersome reconstitution processes. Refrigeration is not always convenient. Thus, there is a need for pirenzepine in a dosage form that solves the physical appearance problem using a formulation approach that is deemed desirable.
Summary of the Invention Accordingly, it is a primary object of the present invention to provide an aqueous ophthalmic formulation, for treating myopia, comprising pirenzepine in combination with a pharmaceutically acceptable gel carrier. Detailed Description of the Preferred Embodiment The ophthalmic aqueous gel formulation of the present invention for treating myopia comprises a pharmaceutically effective amount of pirenzepine in combination with a water soluble cellulose derivative.
The concentration of the pirenzepine in the present formulation may range from about 0.001 to 3% (w/v), preferably about 0.005 to 2% (w/v). Pirenzepine and its dihydrochloride salt are known in the art.
Below is the structure of pirenzepine dihydrochloride:
Figure imgf000004_0001
Molecular formula: Cι9H2ιN5O2 »2 HCl«H2O
Molecular weight: 442.3; 351.4 (anhydrous free base) Chemical Names: 5,11-dihydro-l l-[(4-methyl-l-piperazinyl)acetyl]-6H pyrido[2,3-b][l,4]-benzodiazepin-6-one dihydrochloride monohydrate 1 l-[(4-methyl-l-piperazinyl)acetyl]-pyrido[2,3-b][l,4]- benzodiazepin-6(5H)-one dihydrochloride monohydrate
Cellulose derivatives are used as gelling agents in the formulation of this invention. Most preferred is hydroxypropyl methylcellulose. Any cellulose derived gelling agent, however, that forms an aqueous gel at the desired viscosity, i.e., is soluble in water and forms a gel, can be used. Such derivatives are well known, as are their properties, and are described, e.g., in the U.S. Pharmacopeia (2000) (UNITED STATES PHARMACOPEIAL CONVENTION, INC., THE UNITED STATES PHARMACOPEIA/THE NATIONAL FORMULARY (2000)). Such gelling agents include, but are not limited to, methyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, hydroxyethyl cellulose, and cellulose gum. Combinations of various derivatives may also be used. Cellulose based gelling agents are advantageous over, for example, cross-linked acrylic polymers. For example, Carbopol™, a cross-linked acrylic polymer, has been used to form an aqueous gel containing pilocarpine hydrochloride for ophthalmic use. Cellulose based gelling agents, however, are less likely to cause adverse reactions. The formulations of the invention are substantially viscous enough to form a viscous gel. The viscosity preferably is in the range of 10,000 to 300,000 centipoise (cps), most preferably 15,000-200,000 cps, at about 20 °C and shear rate of Is"1 based on Brookfield RVDV analysis.
In the aqueous gel for ophthalmic use, the amount of cellulose based gelling agent is preferably from about 0.5 wt. % to 5 wt. %, most preferably from about 1 wt. % to 5 wt.
%.
Suitable cellulose based preparations for use in the invention are commonly commercially available. For example, sources of hydroxypropyl methylcellulose that are suitable for making a cellulose based ophthalmic gel according to the invention include Ashland Distribution Co., Asiaamerica International Inc., Biddle Sawyer Corp., Carbomer
Inc., Colorcon Inc., Dow Chemical Co., FOB Chemicals, Hercules Inc., Mutchler Inc., Penta Mfg Co., Spectrum Laboratoiy Products Inc., Van Waters & Rogers Inc., and Warner Jenkinson.
The formulation may contain additional pharmaceutically inactive substances. For example, it may contain one or more solubilizing agents, such as polysorbate 20, polysorbate 40, polysorbate 60, or polysorbate 80. The formulation may also contain a dispersant, such as lecithin or glycerin. Collagen can also be added. Other additives include cyclodextrins, in particular alpha, beta, and gamma cyclodextrins. Also, vitamin E, particularly in solubilized form, or other antioxidants, including butylate hydroxyanisole (BHA) and butylate hydroxytoluene (BHT), may be added. Some additional examples of inactives follow: sodium chloride, cetrimide, thimerosal, benzalkonium chloride, boric acid, sodium carbonate, potassium chloride, propylene glycol, polyoxyethylene, polyoxypropylene, polyoxyl 40 stereate, polyvinyl alcohol, poloxamer 188, sodium citrate, sodium thiosulfate, sodium bisulfite, dextran 70, acetic acid, polyethylene glycol, povidone, dextrose, magnesium chloride, alginic acid, sodium acetate, sodium borate, edetate disodium, sodium hydroxide, and hydrochloric acid. The optimal amount of inactive ingredient employed in the formulation can be conventionally determined based on the particular active pharmaceutical, and the intended use. The formulation of the invention can be placed in any desired dispensing device suitable for an ophthalmic formulation. The device can be an ophthalmic delivery system such as a sterile ophthalmic tube, for example, a conventional 3.5-5 g tube having an ophthalmic tip and containing the ophthalmic formulation of the invention, or a sterile, single or daily use container containing 0.1-0.5 g of the formulation.
The pharmaceutical formulations can be administered via various routes including ocular instillation, subconjuctival administration, and intravitreal administration. A typical daily dose of pirenzepine may range 6 mg or less/whole body weight, preferably 4 mg or less/whole body weight, and can be administered in a single dose or in divided doses. However, it should be understood that the amount of pirenzepine actually administered ought to be determined in light of various relevant factors including the myopia to be treated, the chosen route of administration and the severity of the patient's symptom; and, therefore, the above dose should not be intended to limit the scope of the invention in any way. The stability data generated on the gel and solution dosage forms show the superiority of the gel over the solution in maintaining an acceptable physical appearance in the presence of the small amounts of the water-insoluble degradation product refen-ed to in the background of the invention.
The following Examples are intended to further illustrate the scope of the invention without limiting its scope.
Example 1 An aqueous ophthalmic gel of 2.0% pirenzepine for the treatment of myopia according to the present invention was prepared as follows:
Table 1. Pirenzepine ophthalmic gel formulations.
Figure imgf000007_0001
Part 1 : Purified water was heated to 80-90 °C. Hydroxypropyl methylcellulose (HPMC) was added and mixed until it was uniformly dispersed. The pH was adjusted to 5.0 ± 1.0 with sodium hydroxide, but this was not a critical step and can be eliminated. After being placed in a pressure vessel, the mixture was sterilized at 121 °C for 30-45 minutes. In another embodiment, autoclaving is conducted under nitrogen when oxygen plays a role in viscosity loss upon autoclaving. The mixture was cooled to 25° to 30 °C and mixed for several hours to yield a homogenous viscous gel. Batches manufactured in the appropriate jacketed pressure vessel showed that chilling Part 1 (the hydroxypropyl methylcellulose phase) to about 10 °C rather than to 25° to 30 °C after autoclaving greatly enlianced the hydration and consequently the viscosity of the gel. The gel was stored at 25° to 30 °C for several hours to aid in dissolution and then maintained at 25° to 30 °C for storage.
Part 2: The rest of the ingredients were mixed and dissolved in water until a clear solution was obtained. The pH was adjusted to 5.0 ± 1.0 with sodium hydroxide. The solution was sterilized by membrane filtration (0.2 microns). The concentration of pirenzepine is calculated based on the free base. However, we added its dihydrochloride salt. By adjusting the pH to 5.0 + 1.0 with sodium hydroxide, the dihydrochloride salt is partially or completely converted to the monohydrochloride salt.
The solution of Part 2 was aseptically added to the gel of Part 1. Sufficient sterile water was added to q.s. to the final weight of the batch. A final pH adjustment was made, if necessary. The batch was mixed for about 48 hours to achieve homogeneity. A gel resulted that was used to aseptically fill pre-sterilized ophthalmic containers.
Example 2
The ophthalmic pirenzepine gel preparation made in Example 1 was administered as follows (the ophthalmic tip of the dispensing mechanism did not touch any surface to avoid contamination). The lower lid of the eye to be administered was pulled down and a small amount of gel (approximately 0.25 inches) was applied to the inside of the eyelid. The gel was applied to the afflicted eye twice per day. A gel formulation in a target population of pediatric subjects was well tolerated.
Example 3 Procedure for Viscosity Measurement: A Brookfield Cone and Plate Viscometer (Model RVDV-III+) was used to measure viscosity at about 20°C and shear rate of Is"1.
The viscosities of 0.5 - 2 g samples of various gels were measured. Gels with viscosities of 5,000 to less than 600,000 cps were tested with a CP52 spindle, and other spindles are used depending on the viscosities of the gels.
While the present invention has been described in some detail for purposes of clarity and understanding, one skilled in the art will appreciate that various changes in form and detail can be made without departing from the true scope of the invention. All patents, applications, and publications, referred to above, are hereby incorporated by reference.

Claims

WHAT IS CLAIMED IS:
1. An aqueous ophthalmic gel formulation for the treatment of myopia comprising pirenzepine and an amount of gelling agent effective to form an aqueous gel, said gel having a Brookfield RVDV viscosity of from about 10,000 to about 300,000 cps at about 20°C and sheer rate of Is"1 , wherein said gelling agent is a water soluble cellulose derivative.
2. A formulation according to claim 1 wherein the concentration of said pirenzepine is from about 0.001 to 3 % (w/v).
3. A formulation according to claim 1 wherein the concentration of said pirenzepine is from about 0.005 to 2 % (w/v).
4. A formulation according to claim 1 wherein said water soluble cellulose derivative is soluble in said aqueous formulation at a viscosity of about 15,000 to about 200,000 cps at about 20°C and sheer rate of Is"1 .
5. A formulation according to claim 1 wherein said water soluble cellulose derivative is soluble in said aqueous formulation at a viscosity of about 100,000 cps at about 20°C and sheer rate of Is"1 .
6. A formulation according to claim 1 wherein said amount of gelling agent is an amount of from about 0.5 to 5 wt. %.
7. A formulation according to claim 1 wherein said amount of gelling agent is an amount of from about 1 to 5 wt. %.
S. A formulation according to claim 1, further comprising at least one member selected from the group consisting of sodium chloride, cetrimide, thimerosal, benzalkoniuni chloride, boric acid, sodium carbonate, potassium chloride, propylene glycol, polyoxyethylene, polyoxypropylene, polyoxyl 40 stereate, polyvinyl alcohol, poloxamer 188, sodium citrate, sodium thiosulfate, sodium bisulfite, dextran 70, acetic acid, polyethylene glycol, povidone, dextrose, magnesium chloride, alginic acid, sodium acetate, sodium borate, edetate disodium, sodium hydroxide, and hydrochloric acid.
9. A formulation according to claim 1 wherein said gelling agent is at least one member selected from the group consisting of hydroxypropyl methylcellulose, methyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, hydroxyethyl cellulose, and cellulose gum.
10. A formulation according to claim 1 wherein said gelling agent is hydroxypropyl methylcellulose.
11. An ophthalmic delivery system containing the formulation of claim 1.
12. The ophthalmic delivery system of claim 11 comprising an ophthalmic tube having an ophthalmic tip and containing said aqueous gel.
13. A method of treating myopia comprising administering the formulation of claim 1 to the eye of a human individual, whereby myopia is treated.
14. The method of claim 13 wherein said human individual is a pediatric subject.
15. Use of the formulation of claim 1 in the preparation of a medicament for the treatment of myopia.
16. Use of the foniiulation of claim 1 in the preparation of a medicament for the treatment of myopia in a pediatric subject.
17. A method of making the formulation of claim 1 comprising autoclaving a mixture comprised of said gelling agent and water, sterile filtering a solution comprising said pirenzepine and water, and aseptically admixing them.
18. The method of the claim 17 wherein said autoclaving step is conducted under nitrogen.
19. A foniiulation according to claim 1 wherein the formulation is selected from the group consisting of the formulations of Table 1.
20. A foraiulation according to claim 1 in sterile form.
PCT/US2002/013823 2001-05-25 2002-05-01 Pirenzepine ophthalmic gel WO2002096418A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
IL15890402A IL158904A0 (en) 2001-05-25 2002-05-01 Pirenzepine ophthalmic gel
CA002447562A CA2447562A1 (en) 2001-05-25 2002-05-01 Pirenzepine ophthalmic gel
BR0210013-4A BR0210013A (en) 2001-05-25 2002-05-01 Pyrenzepine Ophthalmic Gel
HU0304071A HUP0304071A2 (en) 2001-05-25 2002-05-01 Pirenzepine ophthalmic gel and process for its preparation
KR10-2003-7015393A KR20040018380A (en) 2001-05-25 2002-05-01 Pirenzepine Ophthalmic Gel
MXPA03010655A MXPA03010655A (en) 2001-05-25 2002-05-01 Pirenzepine ophthalmic gel.
EP02734130A EP1397132A4 (en) 2001-05-25 2002-05-01 Pirenzepine ophthalmic gel
JP2002592928A JP2004531569A (en) 2001-05-25 2002-05-01 Pirenzepine ophthalmic gel
US10/698,320 US20040137069A1 (en) 2001-05-25 2003-10-31 Pirenzepine ophthalmic gel
NO20035224A NO20035224D0 (en) 2001-05-25 2003-11-24 Ophthalmic pirenzepel
US11/400,635 US20060188576A1 (en) 2001-05-25 2006-04-07 Pirenzepine ophthalmic gel

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29373101P 2001-05-25 2001-05-25
US60/293,731 2001-05-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/698,320 Continuation US20040137069A1 (en) 2001-05-25 2003-10-31 Pirenzepine ophthalmic gel

Publications (1)

Publication Number Publication Date
WO2002096418A1 true WO2002096418A1 (en) 2002-12-05

Family

ID=23130330

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/013823 WO2002096418A1 (en) 2001-05-25 2002-05-01 Pirenzepine ophthalmic gel

Country Status (17)

Country Link
US (2) US20040137069A1 (en)
EP (1) EP1397132A4 (en)
JP (1) JP2004531569A (en)
KR (1) KR20040018380A (en)
CN (1) CN1509172A (en)
BR (1) BR0210013A (en)
CA (1) CA2447562A1 (en)
EC (1) ECSP044862A (en)
HU (1) HUP0304071A2 (en)
IL (1) IL158904A0 (en)
MX (1) MXPA03010655A (en)
NO (1) NO20035224D0 (en)
NZ (1) NZ529615A (en)
PL (1) PL366924A1 (en)
RU (1) RU2297831C2 (en)
WO (1) WO2002096418A1 (en)
ZA (1) ZA200309791B (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006008118A1 (en) * 2004-07-16 2006-01-26 Proteosys Ag Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents
CN105663137A (en) * 2016-01-14 2016-06-15 王真 Application of pirenzepine in preparation of medicine for treating pyemia disease
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
EP3463360A4 (en) * 2016-05-25 2020-01-29 Singapore Health Services Pte Ltd Atropine-containing aqueous composition
US10813923B1 (en) 2015-04-23 2020-10-27 Sydnexis, Inc. Ophthalmic composition
US11052094B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
CN113811306A (en) * 2019-03-26 2021-12-17 温桑托尔公司 Topical formulations for the treatment of peripheral neuropathy
US11382909B2 (en) 2014-09-05 2022-07-12 Sydnexis, Inc. Ophthalmic composition
US20220267328A1 (en) * 2017-11-03 2022-08-25 Alcon Inc. Azabicyclo and diazepine derivatives

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4963359B2 (en) * 2005-01-12 2012-06-27 ロート製薬株式会社 Ophthalmic topical preparation
EP2097044A4 (en) * 2006-12-26 2012-10-10 Quadra Logic Tech Inc Drug delivery implants for inhibition of optical defects
US10265265B2 (en) 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
EP2008651A1 (en) 2007-06-26 2008-12-31 Drug Delivery Solutions Limited A bioerodible patch
NZ598483A (en) 2007-09-07 2013-08-30 Quadra Logic Tech Inc Drug cores for sustained release of therapeutic agents
WO2010083129A2 (en) 2009-01-13 2010-07-22 The Regents Of The University Of California Implantable delivery vehicle for ocular delivery of muscarinic antagonists
EP2632468B1 (en) * 2010-10-25 2017-12-13 University Of Manitoba Therapeutic compositions for diabetic symmetrical polyneuropathy
US9610245B2 (en) 2011-03-14 2017-04-04 Drug Delivery Solutions Limited Ophthalmic composition
RU2635185C2 (en) * 2013-12-17 2017-11-09 Иван Дмитриевич Захаров Pharmaceutical preparation for prevention and treatment of progressive myopia
EP3542788A1 (en) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topical composition comprising calcipotriol and betamethasone dipropionate
WO2020251926A1 (en) * 2019-06-10 2020-12-17 Jenivision Inc. Methods and formulations for treating vision disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637604A (en) * 1989-06-21 1997-06-10 The Trustees Of The University Of Pennsylvania Treatment and control of ocular development

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU188852B (en) * 1983-03-16 1986-05-28 Richter Gedeon Vegyeszeti Gyar Rt,Hu Process for producing thiazolidine derivatives active against gastric ulcer and intestinal ulcer
US4865599A (en) * 1986-08-18 1989-09-12 Houston Biotechnology, Inc. Ophthalmic compositions for treating nerve degeneration
CA1336490C (en) * 1988-06-03 1995-08-01 Paul Michael Iuvone Pharmacological treatment of ocular development
US5122522A (en) * 1989-06-21 1992-06-16 The Trustees Of The University Of Pennsylvania Treatment and control of ocular development
US5360801A (en) * 1989-06-21 1994-11-01 The Trustees Of The University Of Pennsylvania Pharmacological stimulation of eye growth
US5055302A (en) * 1990-02-22 1991-10-08 Trustees Of The University Of Pennsylvania Neuropeptide control of ocular growth
US5461808A (en) * 1993-02-08 1995-10-31 Fritts; Robert W. Table top backlit display
US5385939A (en) * 1993-04-30 1995-01-31 The Trustees Of The University Of Pennsylvania GABA-ergic modulation of eye growth
US5461052A (en) * 1993-04-30 1995-10-24 The Trustees Of The University Of Pennsylvania Prevention of myopia by tricyclic compounds
US5516808A (en) * 1994-10-27 1996-05-14 Sawaya; Assad S. Topical cellulose pharmaceutical formulation
US5888493A (en) * 1996-12-05 1999-03-30 Sawaya; Assad S. Ophthalmic aqueous gel formulation and related methods
US6164282A (en) * 1999-01-27 2000-12-26 Allergan Sales, Inc. Methods for restoring and/or enhancing accommodation in pseudo phakia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637604A (en) * 1989-06-21 1997-06-10 The Trustees Of The University Of Pennsylvania Treatment and control of ocular development

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE USPT [online] LATIES ET AL., XP002952205, accession no. WEST *
See also references of EP1397132A4 *

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006008118A1 (en) * 2004-07-16 2006-01-26 Proteosys Ag Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents
JP2008506660A (en) * 2004-07-16 2008-03-06 プロテオシス・アーゲー Muscarinic antagonists with PARP and SIR modulating activity as cytoprotective agents
US8466144B2 (en) 2004-07-16 2013-06-18 Proteosys Ag Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents
US10076515B2 (en) 2014-06-24 2018-09-18 Sydnexis, Inc. Ophthalmic Composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US9770447B2 (en) 2014-06-24 2017-09-26 Sydnexis, Inc. Ophthalmic composition
US11896588B2 (en) 2014-06-24 2024-02-13 Sydnexis, Inc. Ophthalmic composition
US10201534B2 (en) 2014-06-24 2019-02-12 Sydnexis, Inc. Ophthalmic composition
US11890277B2 (en) 2014-06-24 2024-02-06 Sydnexis, Inc. Ophthalmic composition
US11883390B2 (en) 2014-06-24 2024-01-30 Sydnexis, Inc. Ophthalmic composition
US10842787B2 (en) 2014-06-24 2020-11-24 Sydnexis, Inc. Ophthalmic composition
US10864208B2 (en) 2014-06-24 2020-12-15 Sydnexis, Inc. Ophthalmic composition
US11596625B2 (en) 2014-06-24 2023-03-07 Sydnexis, Inc. Ophthalmic composition
US11382909B2 (en) 2014-09-05 2022-07-12 Sydnexis, Inc. Ophthalmic composition
US10953002B2 (en) 2015-04-23 2021-03-23 Sydnexis, Inc. Ophthalmic composition
US10940145B2 (en) 2015-04-23 2021-03-09 Sydnexis, Inc. Ophthalmic composition
US10888557B2 (en) 2015-04-23 2021-01-12 Sydnexis, Inc. Ophthalmic composition
US10813923B1 (en) 2015-04-23 2020-10-27 Sydnexis, Inc. Ophthalmic composition
US11052094B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
US11052095B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
CN105663137A (en) * 2016-01-14 2016-06-15 王真 Application of pirenzepine in preparation of medicine for treating pyemia disease
EP4112055A1 (en) * 2016-05-25 2023-01-04 Singapore Health Services Pte Ltd Atropine-containing aqueous composition
EP3463360A4 (en) * 2016-05-25 2020-01-29 Singapore Health Services Pte Ltd Atropine-containing aqueous composition
US20220267328A1 (en) * 2017-11-03 2022-08-25 Alcon Inc. Azabicyclo and diazepine derivatives
US11884666B2 (en) * 2017-11-03 2024-01-30 Alcon Inc. Azabicyclo and diazepine derivatives
CN113811306A (en) * 2019-03-26 2021-12-17 温桑托尔公司 Topical formulations for the treatment of peripheral neuropathy

Also Published As

Publication number Publication date
IL158904A0 (en) 2004-05-12
CA2447562A1 (en) 2002-12-05
EP1397132A1 (en) 2004-03-17
NZ529615A (en) 2005-07-29
RU2003136735A (en) 2005-03-27
KR20040018380A (en) 2004-03-03
JP2004531569A (en) 2004-10-14
US20040137069A1 (en) 2004-07-15
NO20035224D0 (en) 2003-11-24
PL366924A1 (en) 2005-02-07
ECSP044862A (en) 2004-03-23
MXPA03010655A (en) 2007-06-22
BR0210013A (en) 2004-08-10
ZA200309791B (en) 2004-10-04
US20060188576A1 (en) 2006-08-24
HUP0304071A2 (en) 2004-04-28
EP1397132A4 (en) 2006-12-13
CN1509172A (en) 2004-06-30
RU2297831C2 (en) 2007-04-27

Similar Documents

Publication Publication Date Title
US20060188576A1 (en) Pirenzepine ophthalmic gel
US5888493A (en) Ophthalmic aqueous gel formulation and related methods
US20230181497A1 (en) Ketorolac tromethamine compositions for treating or preventing ocular pain
US5516808A (en) Topical cellulose pharmaceutical formulation
AU674335B2 (en) Ophthalmological preparation
JP7080268B2 (en) Ophthalmic composition containing nitric oxide-releasing prostamide
US20100234336A1 (en) Ophthalmic Compositions
KR101723703B1 (en) Ketorolac tromethamine compositions for treating or preventing ocular pain
JP2729859B2 (en) Reversible thermogelling aqueous pharmaceutical composition
US11969403B2 (en) Topical formulations of chloroprocaine and methods of using same
AU2002305319A1 (en) Pirenzepine ophthalmic gel
EP0056420A1 (en) Ophthalmic gel
US20120028947A1 (en) Ophthalmic Compositions
EP4230193A1 (en) Ophthalmic pharmaceutical composition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10698320

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2447562

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 158904

Country of ref document: IL

Ref document number: 1941/DELNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 02810174X

Country of ref document: CN

Ref document number: 529615

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002592928

Country of ref document: JP

Ref document number: PA/A/2003/010655

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1200301058

Country of ref document: VN

Ref document number: 1020037015393

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002734130

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002305319

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003/09791

Country of ref document: ZA

Ref document number: 200309791

Country of ref document: ZA

WWP Wipo information: published in national office

Ref document number: 2002734130

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 529615

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 529615

Country of ref document: NZ